person · Reporting owner

BJERKHOLT ERIC

Disclosed activity across 9 companies

Tapewire entity: 24148
SEC CIK: 0001197350

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CERUS CORPCERS · Entity 5431	Director	June 09, 2026	June 12, 2026
CalciMedica, Inc.CALC · Entity 7804	Director	August 27, 2024	August 28, 2024
Metagenomi Therapeutics, Inc.MGX · Entity 7270	Director	June 09, 2026	June 11, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	CHIEF FINANCIAL OFFICER	September 11, 2026	September 15, 2026
Surrozen, Inc./DESRZN · Entity 6092	Director	May 13, 2026	May 14, 2026
Viracta Therapeutics, Inc.SNSS · Entity 85616	EVP, CFO & Corp. Secretary	November 30, 2016	December 06, 2016

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CERUS CORP

Report date June 09, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	261,679	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Sale · Disposed 20,454 · Balance 261,679

CalciMedica, Inc.

Report date August 27, 2024 · Filed August 28, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2034-08-26	Direct	10,000	Reported balance After 2024-08-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-08-27 · Grant · Acquired 10,000 · Balance 10,000 F1: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024.

Metagenomi Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-06-08	Direct	21,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Mirum Pharmaceuticals, Inc.

Report date September 11, 2026 · Filed September 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	44,745	Ending reported balance After 2026-09-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-11 · Exercise / conversion · Acquired 18,333 · Balance 54,688 F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Row 2 · 2026-09-14 · Sale · Disposed 9,943 · Balance 44,745 F2: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-09-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-11 · Exercise / conversion · Disposed 18,333 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

F2: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

F3: The restricted stock units vest in a series of three successive equal annual installments beginning on the one-year anniversary of September 11, 2023.

Surrozen, Inc./DE

Report date May 13, 2026 · Filed May 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2036-05-12	Direct	5,550	Reported balance After 2026-05-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-13 · Grant · Acquired 5,550 · Balance 5,550 F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

Viracta Therapeutics, Inc.

Report date November 30, 2016 · Filed December 06, 2016 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2026-11-30	Direct	95,000	Reported balance After 2016-11-30 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2016-11-30 · Grant · Acquired 95,000 · Balance 95,000 F1: Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Twenty-five per cent (25%) of the total shares vest on November 30, 2017 and the remainder will vest ratably on each monthly anniversary thereafter such that the award will be fully vested on November 30, 2020.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aimmune Therapeutics, Inc.

Report date October 10, 2020 · Filed October 14, 2020

Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-10 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-10-10 · Other · Disposed 27,805 · Balance 0 F1: Includes 1,869 shares acquired pursuant to the Issuer's employee stock purchase plan.
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-13 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-10-13 · Disposition to issuer · Disposed 23,905 · Balance 0 F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.44	Direct	Reported balance After 2020-10-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-13 · Disposition to issuer · Disposed 264,800 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.07	Direct	Reported balance After 2020-10-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-13 · Disposition to issuer · Disposed 56,250 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.72	Direct	Reported balance After 2020-10-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-13 · Disposition to issuer · Disposed 78,750 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.81	Direct	Reported balance After 2020-10-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-10-13 · Disposition to issuer · Disposed 56,250 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,869 shares acquired pursuant to the Issuer's employee stock purchase plan.

F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").

F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

CHINOOK THERAPEUTICS, INC.

Report date August 11, 2023 · Filed August 11, 2023

Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-08-11 transaction · row 1 1 source row Row 1 · 2023-08-11 · Disposition to issuer · Disposed 39,371 · Balance 0 F1: The number of shares reported includes 504 shares of the Issuer's Common Stock acquired, since that date of the reporting person's previous Form 4 filing, pursuant to the Issuer's employee stock purchase plan in transactions exempt from reporting under Rules 16b-3(c) and 16b-3(d). F2: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2030-11-29	Direct	Reported balance After 2023-08-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-08-11 · Disposition to issuer · Disposed 144,787 · Balance 0 F3: This stock option award, which provided for 25% of the award to vest on November 30, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.14 · Expires 2031-02-09	Direct	Reported balance After 2023-08-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-08-11 · Disposition to issuer · Disposed 21,501 · Balance 0 F4: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.90 · Expires 2032-01-31	Direct	Reported balance After 2023-08-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-08-11 · Disposition to issuer · Disposed 88,000 · Balance 0 F5: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.27 · Expires 2033-01-30	Direct	Reported balance After 2023-08-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-08-11 · Disposition to issuer · Disposed 84,000 · Balance 0 F6: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-08-11 · Disposition to issuer · Disposed 16,415 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F8: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-08-11 · Disposition to issuer · Disposed 2,435 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-08-11 · Disposition to issuer · Disposed 14,667 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-08-11 · Disposition to issuer · Disposed 21,000 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-08-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-08-11 · Disposition to issuer · Disposed 8,400 · Balance 0 F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F12: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Filing footnotes · ownership attribution and instrument terms

F1: The number of shares reported includes 504 shares of the Issuer's Common Stock acquired, since that date of the reporting person's previous Form 4 filing, pursuant to the Issuer's employee stock purchase plan in transactions exempt from reporting under Rules 16b-3(c) and 16b-3(d).

F2: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.

F3: This stock option award, which provided for 25% of the award to vest on November 30, 2021 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F4: This stock option award, which provided for 25% of the award to vest on February 10, 2022 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F5: This stock option award, which provided for 25% of the award to vest on January 31, 2023 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F6: This stock option award, which provided for 25% of the award to vest on January 31, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F7: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F8: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on November 30, 2021. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F9: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 10, 2022. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F10: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2023. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F11: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on January 31, 2024. Pursuant to the Merger Agreement, at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

F12: When granted, the RSU award provided for the vesting of restricted stock units for shares of the Issuer's Common Stock contingent upon the achievement of certain performance-based vesting conditions. Pursuant to the Merger Agreement, at the effective time of the Merger, the performance-based RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Corium International, Inc.

Report date November 27, 2018 · Filed November 29, 2018

Section 16 reporting ended · disclosed 2018-11-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy The Bjerkholt Family Irrevocable Trust	Reported balance After 2018-11-27 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-11-27 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
Common StockSEC Table I · non-derivative	IndirectBy The Bjerkholt Children's Irrevocable Trust	Reported balance After 2018-11-27 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.97 · Expires 2025-04-13	Direct	Reported balance After 2018-11-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-11-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.19 · Expires 2025-12-17	Direct	Reported balance After 2018-11-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-11-27 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2026-12-21	Direct	Reported balance After 2018-11-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2027-11-30	Direct	Reported balance After 2018-11-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-11-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR").

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2022 Filed Jun 3, 2022 21:08 UTC	CERUS CORP CERS · Entity 5431	GrantCommon Stock	20,454	$0.00	$0.00	Disclosure SEC source: 0001209191-22-034203 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,133 F1 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document
February 11, 2022 Filed Feb 14, 2022 19:58 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	SaleCommon Stock	895	$12.74	$11,403.37	Disclosure SEC source: 0001209191-22-009565 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,203 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document
February 10, 2022 Filed Feb 14, 2022 19:58 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionRestricted Stock Units (RSU) · Derivative	2,434	$0.00	$0.00	Disclosure SEC source: 0001209191-22-009565 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,870 Underlying: Common Stock · 2,434 shares Expires 2024-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
February 10, 2022 Filed Feb 14, 2022 19:58 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	2,434	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-009565 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 31, 2022 Filed Feb 2, 2022 17:23 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantRestricted Stock (RSU)(Common Stock) · Derivative	22,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-006449 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2025-01-31 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
January 31, 2022 Filed Feb 2, 2022 17:23 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (right to buy) · Derivative	88,000	$0.00 Strike: $12.90	$0.00	Disclosure SEC source: 0001209191-22-006449 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2032-01-30 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 31, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
December 01, 2021 Filed Dec 3, 2021 19:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionRestricted Stock Units (RSU) · Derivative	16,414	$0.00	$0.00	Disclosure SEC source: 0001209191-21-067993 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,829 Underlying: Common Stock · 16,414 shares Expires 2031-11-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vest as to 33.33% of the total shares on November 30, 2021, and thereafter vests as to 33.33% of the total RSUs on November 30, 2022, and as to 33.33% of the total RSUs on November 30, 2023, subject to the provision of services to the Company on each vesting date. Read SEC document
December 01, 2021 Filed Dec 3, 2021 19:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Tax withholdingCommon Stock	5,750	$16.02	$92,097.18	Disclosure SEC source: 0001209191-21-067993 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,664 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document
December 01, 2021 Filed Dec 3, 2021 19:05 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Exercise / conversionCommon Stock	16,414	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-067993 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 02, 2021 Filed Jun 3, 2021 23:59 UTC	CERUS CORP CERS · Entity 5431	GrantOption (Right to Buy) · Derivative	29,983	Not disclosed Strike: $5.62	Not disclosed	Disclosure SEC source: 0001209191-21-037961 · doc4.xml · derivative · entry 4 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,983 Underlying: Common Stock · 29,983 shares Expires 2031-06-01 F4 · price: Not applicable. F5 · derivative.exercise_date: The option shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2022 Annual Meeting of Stockholders. Read SEC document
June 02, 2021 Filed Jun 3, 2021 23:59 UTC	CERUS CORP CERS · Entity 5431	GrantCommon Stock	14,888	$0.00	$0.00	Disclosure SEC source: 0001209191-21-037961 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,679 F2 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document
June 02, 2021 Filed Jun 4, 2021 22:34 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantEmployee Stock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $4.07	$0.00	Disclosure SEC source: 0001209191-21-038384 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-01 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 01, 2021 Filed Jun 3, 2021 23:59 UTC	CERUS CORP CERS · Entity 5431	Exercise / conversionRestricted Stock Unit · Derivative	13,228	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-037961 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,228 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. F4 · price: Not applicable. F3 · derivative.exercise_date: This RSU vested one year from the date of grant. F3 · derivative.expiration_date: This RSU vested one year from the date of grant. Read SEC document
June 01, 2021 Filed Jun 3, 2021 23:59 UTC	CERUS CORP CERS · Entity 5431	Exercise / conversionCommon Stock	13,228	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-037961 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document
February 10, 2021 Filed Feb 12, 2021 18:08 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantRestricted Stock (RSU)(Common Stock) · Derivative	7,304	$0.00	$0.00	Disclosure SEC source: 0001209191-21-010381 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,304 Underlying: Common Stock · 7,304 shares Expires 2024-02-10 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date. Read SEC document
February 10, 2021 Filed Feb 12, 2021 18:08 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (right to buy) · Derivative	21,501	$0.00 Strike: $15.14	$0.00	Disclosure SEC source: 0001209191-21-010381 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,501 Underlying: Common Stock · 21,501 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 10, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
November 30, 2020 Filed Dec 18, 2020 19:02 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantRestricted Stock Units · Derivative	49,243	$0.00	$0.00	Disclosure SEC source: 0001209191-20-064518 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,243 Underlying: Common Stock · 49,243 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs shall vest as to 33.33% of the total shares on November 30, 2021, and thereafter vests as to 33.33% of the total RSUs on November 30, 2022, and as to 33.33% of the total RSUs on November 30, 2023, subject to the provision of services to the Company on each vesting date. F3 · derivative.expiration_date: The RSUs shall vest as to 33.33% of the total shares on November 30, 2021, and thereafter vests as to 33.33% of the total RSUs on November 30, 2022, and as to 33.33% of the total RSUs on November 30, 2023, subject to the provision of services to the Company on each vesting date. Read SEC document
November 30, 2020 Filed Dec 18, 2020 19:02 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantEmployee Stock Option (right to buy) · Derivative	144,787	$0.00 Strike: $13.98	$0.00	Disclosure SEC source: 0001209191-20-064518 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,787 Underlying: Common Stock · 144,787 shares Expires 2030-11-29 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on November 30, 2021, and thereafter vests as to 1/36 of the remaining shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Disposition to issuerStock Option (right to buy) · Derivative	56,250	$10.69 Strike: $23.81	$601,312.50	Disclosure SEC source: 0000899243-20-028176 · doc4.xml · derivative · entry 6 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,250 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Disposition to issuerStock Option (right to buy) · Derivative	78,750	$10.78 Strike: $23.72	$848,925.00	Disclosure SEC source: 0000899243-20-028176 · doc4.xml · derivative · entry 5 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,750 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Disposition to issuerStock Option (right to buy) · Derivative	56,250	$0.43 Strike: $34.07	$24,187.50	Disclosure SEC source: 0000899243-20-028176 · doc4.xml · derivative · entry 4 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,250 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Disposition to issuerStock Option (right to buy) · Derivative	264,800	$15.06 Strike: $19.44	$3,987,888.00	Disclosure SEC source: 0000899243-20-028176 · doc4.xml · derivative · entry 3 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 264,800 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document
October 13, 2020 Filed Oct 14, 2020 20:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Disposition to issuerCommon Stock, $0.0001 par value	23,905	$34.50	$824,722.50	Disclosure SEC source: 0000899243-20-028176 · doc4.xml · nonDerivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F3 · shares: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. Read SEC document
October 10, 2020 Filed Oct 14, 2020 20:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	OtherCommon Stock, $0.0001 par value	27,805	$34.50	$959,272.50	Disclosure SEC source: 0000899243-20-028176 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 1,869 shares acquired pursuant to the Issuer's employee stock purchase plan. Read SEC document
October 05, 2020 Filed Oct 6, 2020 01:13 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Exercise / conversionStock Option (Right to Buy) · Derivative	5,200	$0.00 Strike: $19.44	$0.00	Disclosure SEC source: 0000899243-20-027457 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,800 Underlying: Common Stock · 5,200 shares Expires 2027-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document
October 05, 2020 Filed Oct 6, 2020 01:13 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Exercise / conversionCommon Stock, $0.0001 par value	5,200	$19.44	$101,088.00	Disclosure SEC source: 0000899243-20-027457 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the adjusted total which includes a purchase of 94 shares under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c). F2 · balance_after: Includes 9,375 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F3 · balance_after: Includes 9,843 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F4 · balance_after: Includes 7,031 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
October 05, 2020 Filed Oct 6, 2020 21:58 UTC	CERUS CORP CERS · Entity 5431	Exercise / conversionRestricted Stock Unit · Derivative	4,281	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-054074 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,281 Underlying: Common Stock · 4,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. Read SEC document
October 05, 2020 Filed Oct 6, 2020 21:58 UTC	CERUS CORP CERS · Entity 5431	Exercise / conversionCommon Stock	4,281	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-054074 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document
September 24, 2020 Filed Sep 28, 2020 21:37 UTC	CalciMedica, Inc. GRAY · Entity 7804	GrantDirector Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-20-052239 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-09-23 F1 · derivative.exercise_date: The option shall vest as to 1/36th of the total shares on October 24, 2020 and on each monthly anniversary thereafter such that the option shall be fully vested on September 24, 2023, subject to the continued service of the Reporting Person to the Issuer through each vesting date. Read SEC document
September 15, 2020 Filed Sep 16, 2020 21:18 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Tax withholdingCommon Stock, $0.0001 par value	840	$34.25	$28,770.00	Disclosure SEC source: 0000899243-20-025348 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,547 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F2 · balance_after: Includes 9,375 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F3 · balance_after: Includes 9,843 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F4 · balance_after: Includes 7,031 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
June 03, 2020 Filed Jun 5, 2020 22:47 UTC	CERUS CORP CERS · Entity 5431	GrantRestricted Stock Unit · Derivative	13,228	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-034813 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,228 Underlying: Common Stock · 13,228 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The Restricted Stock Unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. F4 · derivative.expiration_date: The Restricted Stock Unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. Read SEC document
June 03, 2020 Filed Jun 5, 2020 22:47 UTC	CERUS CORP CERS · Entity 5431	GrantOption (Right to Buy) · Derivative	28,177	Not disclosed Strike: $6.37	Not disclosed	Disclosure SEC source: 0001209191-20-034813 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,177 Underlying: Common Stock · 28,177 shares Expires 2030-06-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The Option shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2021 Annual Meeting of Stockholders. Read SEC document
May 10, 2020 Filed May 12, 2020 21:24 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantCommon Stock, $0.0001 par value	2,420	$0.00	$0.00	Disclosure SEC source: 0000899243-20-012859 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,387 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the "Vesting Date"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the "Vesting Date"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date. F2 · balance_after: Includes 9,375 RSUs and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F3 · balance_after: Includes 9,843 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F4 · balance_after: Includes 7,031 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
March 12, 2020 Filed Mar 13, 2020 01:13 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	PurchaseCommon Stock, $0.0001 par value	1,000	$15.10	$15,100.00	Disclosure SEC source: 0000899243-20-008140 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,967 F1 · balance_after: Includes 9,375 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F2 · balance_after: Includes 9,843 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 7,031 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
March 09, 2020 Filed Mar 11, 2020 00:47 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	PurchaseCommon Stock, $0.0001 par value	1,000	$18.97	$18,970.00	Disclosure SEC source: 0000899243-20-007813 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,967 F1 · balance_after: Includes 9,375 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F2 · balance_after: Includes 9,843 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 7,031 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
March 02, 2020 Filed Mar 5, 2020 02:36 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Tax withholdingCommon Stock, $0.0001 par value	1,982	$23.81	$47,191.42	Disclosure SEC source: 0000899243-20-007096 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,967 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F2 · balance_after: Includes 9,375 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F3 · balance_after: Includes 9,843 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F4 · balance_after: Includes 7,031 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
February 28, 2020 Filed Mar 4, 2020 01:36 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantStock Option (right to buy) · Derivative	56,250	$0.00 Strike: $23.81	$0.00	Disclosure SEC source: 0000899243-20-006852 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 56,250 shares Expires 2030-02-28 F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
February 28, 2020 Filed Mar 4, 2020 01:36 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantCommon Stock, $0.0001 par value	9,375	$0.00	$0.00	Disclosure SEC source: 0000899243-20-006852 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,949 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 13,125 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 9,375 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
January 29, 2020 Filed Feb 4, 2020 01:16 UTC	CERUS CORP CERS · Entity 5431	PurchaseCommon Stock	20,000	$4.15	$83,000.00	Disclosure SEC source: 0001209191-20-006138 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,282 Read SEC document
October 04, 2019 Filed Oct 4, 2019 23:18 UTC	CERUS CORP CERS · Entity 5431	Exercise / conversionRestricted Stock Unit · Derivative	4,282	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-052609 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,562 Underlying: Common Stock · 4,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. F2 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on anniversary of the date of grant. Read SEC document
October 04, 2019 Filed Oct 4, 2019 23:18 UTC	CERUS CORP CERS · Entity 5431	Exercise / conversionCommon Stock	4,282	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-052609 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document
September 18, 2019 Filed Sep 20, 2019 12:55 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	PurchaseCommon Stock, $0.0001 par value	1,550	$22.57	$34,976.68	Disclosure SEC source: 0000899243-19-023984 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,574 F1 · balance_after: Includes shares represented by restricted stock units ("RSUs") and will be settled in common stock upon vesting over a specified time, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
June 05, 2019 Filed Jun 7, 2019 20:31 UTC	CERUS CORP CERS · Entity 5431	GrantRestricted Stock Unit · Derivative	11,184	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-035549 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,184 Underlying: Common Stock · 11,184 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit shall vest one year from the date of grant. F4 · derivative.expiration_date: The restricted stock unit shall vest one year from the date of grant. Read SEC document
June 05, 2019 Filed Jun 7, 2019 20:31 UTC	CERUS CORP CERS · Entity 5431	GrantOption (Right to Buy) · Derivative	23,703	Not disclosed Strike: $4.80	Not disclosed	Disclosure SEC source: 0001209191-19-035549 · doc4.xml · derivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,703 Underlying: Common Stock · 23,703 shares Expires 2029-06-04 F2 · price: Not applicable. F1 · derivative.exercise_date: The option shall vest one year from the date of grant. Read SEC document
March 01, 2019 Filed Feb 14, 2020 22:26 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Tax withholdingCommon Stock, $0.0001 par value	833	$24.30	$20,244.07	Disclosure SEC source: 0000899243-20-004697 · doc5.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,741 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F2 · balance_after: Includes 8,542 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 13,125 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
February 22, 2019 Filed Feb 26, 2019 21:06 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantStock Option (right to buy) · Derivative	78,750	$0.00 Strike: $23.72	$0.00	Disclosure SEC source: 0000899243-19-004863 · doc4.xml · derivative · entry 2 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2029-02-22 F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
February 22, 2019 Filed Feb 26, 2019 21:06 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantCommon Stock, $0.0001 par value	13,125	$0.00	$0.00	Disclosure SEC source: 0000899243-19-004863 · doc4.xml · nonDerivative · entry 1 BJERKHOLT ERIC · CIK 0001197350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,857 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 9,375 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 247 shares acquired on November 15, 2018 pursuant to Issuer's employee stock purchase plan. Read SEC document
November 27, 2018 Filed Nov 29, 2018 00:45 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	15,000	$12.50 Strike: $11.59	$187,500.00	Disclosure SEC source: 0001567619-18-007062 · doc1.xml · derivative · entry 6 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-11-30 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document
November 27, 2018 Filed Nov 29, 2018 00:45 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	15,000	$12.50 Strike: $4.59	$187,500.00	Disclosure SEC source: 0001567619-18-007062 · doc1.xml · derivative · entry 5 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-12-21 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document
November 27, 2018 Filed Nov 29, 2018 00:45 UTC	Corium International, Inc. CORI · Entity 162158	Disposition to issuerDirector Stock Option (Right to Buy) · Derivative	12,000	$12.50 Strike: $7.19	$150,000.00	Disclosure SEC source: 0001567619-18-007062 · doc1.xml · derivative · entry 4 BJERKHOLT ERIC · CIK 0001197350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2025-12-17 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), between Corium International, Inc. (the "Company"), Gurnet Holding Company ("Parent") and Gurnet Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each issued and outstanding share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive (i) $12.50 per Share in cash, plus (ii) one non-transferable contingent value right per Share, which represents the contractual right to receive $0.50 per Share in cash (a "CVR"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each option to purchase Shares that was vested and outstanding was cancelled and converted into the right to receive (i) an amount in cash equal to the product of (x) the number of vested Shares issuable under such option multiplied by (y) the excess of (A) $12.50 over (B) the per share exercise price of such option, plus (ii) one CVR for each Share issuable under such option. This option is fully vested. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.